Comparison of two experimental thrombosis models in rats effects of four glycosaminoglycans - PubMed (original) (raw)
Comparative Study
. 1989 Jun 1;54(5):399-410.
doi: 10.1016/0049-3848(89)90210-7.
Affiliations
- PMID: 2549654
- DOI: 10.1016/0049-3848(89)90210-7
Comparative Study
Comparison of two experimental thrombosis models in rats effects of four glycosaminoglycans
G M Vogel et al. Thromb Res. 1989.
Abstract
Two experimental thrombosis models in rats have been compared with regard to the composition of the formed thrombi and the effects of various treatments on thrombus formation. In the first model thrombosis is induced in the vena cava by a combination of venous stasis and hypercoagulability; these thrombi consist merely of red cells and fibrin with only a few platelets. In the second model thrombosis is induced in an arterio-venous shunt in which the formed thrombi consist of red cells, fibrin and a large amount of platelet aggregates adhering to the foreign material. Antiplatelet serum and acetylsalicylic acid, which reduce blood platelet activity, inhibited thrombus formation only in the arteriovenous shunt model. Dicumoxane, an oral anticoagulant, was active in both models. The glycosaminoglycans heparin, Org 10172, Fragmin and the pentasaccharide, representing the AT-III binding sequence of heparin, were active in both models. However, there were qualitative and quantitative differences between the effects of the glycosaminoglycans suggesting differences in their modes of action.
Similar articles
- Pentasaccharide and Orgaran arrest, whereas heparin delays thrombus formation in a rat arteriovenous shunt.
Vogel GM, van Amsterdam RG, Kop WJ, Meuleman DG. Vogel GM, et al. Thromb Haemost. 1993 Jan 11;69(1):29-34. Thromb Haemost. 1993. PMID: 8446935 - A novel anti-thrombotic heparinoid (Org 10172) devoid of bleeding inducing capacity: a survey of its pharmacological properties in experimental animal models.
Meuleman DG, Hobbelen PM, van Dedem G, Moelker HC. Meuleman DG, et al. Thromb Res. 1982 Aug 1;27(3):353-63. doi: 10.1016/0049-3848(82)90082-2. Thromb Res. 1982. PMID: 6182627 - Orgaran (Org 10172): its pharmacological profile in experimental models.
Meuleman DG. Meuleman DG. Haemostasis. 1992;22(2):58-65. doi: 10.1159/000216296. Haemostasis. 1992. PMID: 1379965 Review. - Different antithrombotic mechanisms among glycosaminoglycans revealed with a new fucosylated chondroitin sulfate from an echinoderm.
Pacheco RG, Vicente CP, Zancan P, Mourão PA. Pacheco RG, et al. Blood Coagul Fibrinolysis. 2000 Sep;11(6):563-73. doi: 10.1097/00001721-200009000-00009. Blood Coagul Fibrinolysis. 2000. PMID: 10997797 - Pharmacological and clinical studies with Lomoparan, a low molecular weight glycosaminoglycan.
Nurmohamed MT, Fareed J, Hoppensteadt D, Walenga JM, ten Cate JW. Nurmohamed MT, et al. Semin Thromb Hemost. 1991;17 Suppl 2:205-13. Semin Thromb Hemost. 1991. PMID: 1948091 Review. No abstract available.
Cited by
- Establishment of a mouse model for ovarian cancer-associated venous thromboembolism.
Ma S, Yin S, Zheng Y, Zang R. Ma S, et al. Exp Biol Med (Maywood). 2023 Jan;248(1):26-35. doi: 10.1177/15353702221118533. Epub 2022 Aug 29. Exp Biol Med (Maywood). 2023. PMID: 36036485 Free PMC article. - MARTX toxin of Vibrio vulnificus induces RBC phosphatidylserine exposure that can contribute to thrombosis.
Chung HY, Bian Y, Lim KM, Kim BS, Choi SH. Chung HY, et al. Nat Commun. 2022 Aug 17;13(1):4846. doi: 10.1038/s41467-022-32599-0. Nat Commun. 2022. PMID: 35978022 Free PMC article. - Animal models of venous thrombosis.
Albadawi H, Witting AA, Pershad Y, Wallace A, Fleck AR, Hoang P, Khademhosseini A, Oklu R. Albadawi H, et al. Cardiovasc Diagn Ther. 2017 Dec;7(Suppl 3):S197-S206. doi: 10.21037/cdt.2017.08.10. Cardiovasc Diagn Ther. 2017. PMID: 29399523 Free PMC article. Review. - Effects of Rivaroxaban on Platelet Activation and Platelet-Coagulation Pathway Interaction: In Vitro and In Vivo Studies.
Perzborn E, Heitmeier S, Laux V. Perzborn E, et al. J Cardiovasc Pharmacol Ther. 2015 Nov;20(6):554-62. doi: 10.1177/1074248415578172. Epub 2015 Apr 6. J Cardiovasc Pharmacol Ther. 2015. PMID: 25848131 Free PMC article. - Isolation and characterization of a heparin with low antithrombin activity from the body of Styela plicata (Chordata-Tunicata). Distinct effects on venous and arterial models of thrombosis.
Santos JC, Mesquita JM, Belmiro CL, da Silveira CB, Viskov C, Mourier PA, Pavão MS. Santos JC, et al. Thromb Res. 2007;121(2):213-23. doi: 10.1016/j.thromres.2007.03.025. Epub 2007 May 4. Thromb Res. 2007. PMID: 17482241 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical